HCV New Drug Research: Video; New Therapies for Hepatitis C

Video; New Therapies for Hepatitis C

Wednesday, July 6, 2011
Posted by New HCV Drugs
File Under boceprevir-victrelis, telaprevir-incivek, video

Dr. Donald Jensen and Dr. Andrew Aronsohn of the University of Chicago Center for Liver Diseases discuss boceprevir and telaprevir, two recently approved therapies for hepatitis C.

0 comments:

Post a Comment

DDW 2012
Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week® (DDW) 2012, the largest and most prestigious gastroenterology meeting, from May 19-22, 2012, at the San Diego Convention Center, CA. DDW, the annual meeting of the American Gastroenterological Association (AGA) Institute, is jointly sponsored by the American Association for the Study of Liver Diseases, the AGA, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract.
Click here for updates

May 18-2012
U.S. health officials want all baby boomers to get tested for hepatitis C.
The Centers for Disease Control and Prevention on Friday released draft recommendations calling for all baby boomers to get a one-time blood test for the liver disease. That's everyone born from 1945 to 1965.
CDC - Draft Recommendations

Find Hepatitis Testing Year Round Near You
Locate organizations offering Hepatitis testing and additional services vaccines and treatment in the NPIN Organizations Database.

Blog Updates
HCV InTheNews
Incivek/Telaprevir
Victrelis/Boceprevir
Telaprevir with VX-222

Archives 2011-2010
Telaprevir
Boceprevir

Hepatitis C Treatment
New targets for antiviral therapy
Side effects-direct-acting antivirals

New Drug Pipeline
New drugs in development for the treatment of hepatitis C

May Updates
Standardization of Terminology of Virological Response in the Treatment of Chronic Hepatitis C

A special supplementary issue of Gastroenterology with full text viral hepatitis review articles and commentaries available through open access. Click here to view an index of articles.

A Few Topics Include;
Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus

Will Interferon-Free Regimens Prevail?

Books
Free from Hepatitis C
About the Author
Lucinda K. Porter, RN is an active hepatitis C advocate who writes, teaches, and lectures on the topic. She is recognized as a leader in her field based upon her professional experience and her first hand knowledge of living with the disease.

Ms. Porter has been a research nurse at Stanford University Medical Center specializing in HCV and her articles and guides have appeared in numerous HCV newsletters and journals.

Today, in addition to being a highly sought-after speaker, she continues to work with various HCV groups on behalf of patients and their families

EASL-Liver Cancer
2012-New guidelines on the management of hepatocellular carcinoma (HCC).
These guidelines result from a joint collaboration between the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC).

EASL-Hepatitis B
EASL-April 2012 Revised Clinical Practice Guidelines on the Management of Chronic Hepatitis B

New Digital Liver Disease Journal - "Clinical Liver Disease" has arrived
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, full data, and download files in either HTML or PDF formats

Projects In Knowledge
Offered at the site is a program series of HCV Video Case Vignettes. In the videos individual patient case studies are discussed, topics include side effects, drug-drug interactions, treatment duration, and outcome.

AASLD - Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.

2012
March 2012-New Antiviral Agents for Hepatitis C
This article describes the direct acting antivirals and host-targeted agents that have recently been approved or have been tested in HCV-infected patients and discusses their two current paths of clinical development: with or without interferon-α.

Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex. These expected developments represent a significant challenge and will stretch current resources.
The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

2011
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Updated Feb-2012
If you have just been diagnosed with hepatitis C or considering HCV therapy click here for easy to understand information.

Drug Interaction Charts
Telaprevir/Boceprevir/Peg-IFN alfa

Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs

Medication Guides;
Telaprevir/Incivek Prescribing Information
Medication Guide
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Peginterferon alfa
Ribavirin

Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.

SUPPORT
A new national toll-free helpline has been launched for people affected by hepatitis C: 877-HELP-4-HEP (877-435-7443).
This new consumer-run helpline is staffed by specially trained peer counselors Monday through Friday, 9am to 7pm EST to provide emotional support, health information, and referrals.
HELP-4-HEP is a partnership among several well-known and nationally recognized nonprofits with a combined 90+ years’ experience in hepatitis C education, support and patient advocacy.

To Learn More Visit The Website

GET TESTED

Click here to order a FREE Home Access Hepatitis C Test Kit

How Soon Should I Get Tested After Exposure ?

After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;

FAIR USE NOTICE:

If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice